Rocket Pharmaceuticals, Inc. (RCKT)
| Market Cap | 1.64B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -185.74M |
| Shares Out | 64.44M |
| EPS (ttm) | -2.72 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 219,874 |
| Open | 24.86 |
| Previous Close | 25.00 |
| Day's Range | 23.66 - 25.62 |
| 52-Week Range | 21.38 - 67.48 |
| Beta | 1.55 |
| Analysts | Strong Buy |
| Price Target | 69.78 (+174.8%) |
| Earnings Date | Nov 3, 2021 |
About RCKT
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has four clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; pyruvate kinase deficiency, a rare red blood ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for RCKT stock is "Strong Buy." The 12-month stock price forecast is 69.78, which is an increase of 174.83% from the latest price.
News
Rocket Pharmaceuticals Appoints Martin L. Wilson as General Counsel and Chief Compliance Officer
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...
Rocket Pharmaceuticals to Host In-Person Investor and Analyst Event and Webcast on Tuesday, Dec. 14 at 7:30 a.m. ET t...
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...
Rocket Pharmaceuticals Announces Participation in Evercore ISI 4th Annual HEALTHCONx Virtual Conference
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...
Rocket Pharma To Test Lower Dose Of Gene Therapy In Genetic Disorder Trial
Rocket Pharmaceuticals Inc (NASDAQ: RCKT) has announced updated data from the Phase 1 trial evaluating a single intravenous infusion of RP-A501, an investigational gene therapy, for Danon Disease. Dano...
Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial of RP-A501 in Danon Disease
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...
Rocket Pharmaceuticals to Host Webcast on Nov. 15 at 8:30 a.m. ET to Present Updated Danon Disease Clinical Data
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...
Rocket Pharmaceuticals Announces Participation in Stifel 2021 Virtual Healthcare Conference
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...
Rocket Pharmaceuticals Announces Danon Disease Presentation at the American Heart Association (AHA) Scientific Sessio...
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...
Rocket Pharmaceuticals Announces Presentations Highlighting Three Lentiviral Gene Therapies at the 63rd American Soci...
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...
Rocket Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Progress
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...
Rocket Pharma Posts Interim Data From Immunodeficiency Disorder Gene Therapy Trial
Rocket Pharmaceuticals Inc (NASDAQ: RCKT) has announced interim data updates from seven patients from the RP-L201 Phase 1/2 trial for Leukocyte Adhesion Deficiency-I (LAD-I). Data were shared at the Ann...
Rocket Pharmaceuticals Announces Positive Clinical Data from RP-L201 Trial for the Treatment of LAD-I at the 28th Ann...
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 28th Annual Congress of ...
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...
Rocket Pharmaceuticals to Present at the 2021 Cell & Gene Meeting on the Mesa
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...
Rocket Pharmaceuticals to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...
Rocket Pharmaceuticals Presents Clinical Data from RP-A501 Trial in Danon Disease at the Heart Failure Society of Ame...
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...
Rocket Pharmaceuticals Announces Upcoming Danon Disease Presentation at the Heart Failure Society of America Annual S...
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...
Rocket Pharmaceuticals Appoints Isabel Carmona, J.D., as Chief Human Resources Officer
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...
Rocket Pharmaceuticals Announces $26.4 Million Private Placement
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...
FDA Lifts Clinical Hold On Rocket Pharma's X-Linked Inherited Disorder Trial
The FDA has lifted the clinical hold on Rocket Pharmaceuticals Inc's (NASDAQ:RCKT) Phase 1 trial of RP-A501 (gene therapy) for Danon Disease, allowing patient enrollment to resume. The hold was removed...
Rocket Pharmaceuticals Announces FDA Lifts Clinical Hold on Danon Disease Trial of RP-A501
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...
Rocket Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Progress
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...
Rocket Pharmaceuticals to Host Conference Call on Aug. 9 at 4:30 p.m. ET to Discuss Second Quarter Results and Recent...
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...
Rocket Pharmaceuticals Announces Positive Data From RP-L102, RP-L201 Gene Therapy Programs
Rocket Pharmaceuticals Inc (NASDAQ: RCKT) has announced positive data from its Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), and Pyruvate Kinase Deficiency (PKD) gene therapy programs. D...